The compound is not a peptide, and no controlled human fat-loss trial was identified
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Every vial goes through careful testing and quality control processes
A specialized compounding pharmacy follows strict protocols to ensure purity, potency, and stability
By purchasing, the customer acknowledges they are qualified to handle and use these materials, and that Regentide shall not be held liable for any misuse.
You can search for a local test provider online
